Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure

Summary

To test whether treatment with the angiotensin II receptor antagonist Irbesartan improves insulin sensitivity and metabolic profile in patients with chronic heart failure.

Timeline

Start

2004-07

Primary completion

—

Completion

2007-06

Outcome

Met primary endpoint

paper Insulin sensitivity improved by 26% (p<0.001) in the irbesartan group, but not in the placebo group (treatment effect: 1.044 min(-1)·μU·ml(-1)·10(4); 95%CI 0.45 to 1.64, p=0.0026). PMID 21856022 ↗

Publications

• Doehner W, Todorovic J, Kennecke C, Rauchhaus M, Sandek A, Lainscak M, van Linthout S, Tschope C, von Haehling S, Anker SD. Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study. Int J Cardiol. 2012 Nov 29;161(3):137-42. doi: 10.1016/j.ijcard.2011.07.051.

Drugs

Indications